Development of Novel Radiotracers for Oncology
A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Biopharmaceutics".
Deadline for manuscript submissions: closed (30 April 2021) | Viewed by 318
Special Issue Editor
Interests: experimental oncology; in vivo tumor models; molecular imaging with SPECT/PET radiotarcers; translationsal research
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
The early detection of primary tumors and metastatic lesions using non-invasive imaging techniques is critical for the prognosis and the outcome of different malignancies. Among in vivo functional imaging techniques, PET and SPECT are the most sophisticated methods that make it possible to detect tumors and metastases with high accuracy and sensitivity with the help of specific radiopharmaceuticals. There are several tumor-associated molecules (e.g.: HER2, PSMA, APN/CD13, etc.) that are important diagnostic and prognostic markers, and promising targets for anti-tumor therapies. The ability to visualize these molecules in solid tumors using in vivo molecular imaging methods allow the non-invasive monitoring of anti-cancer treatments and the planning of radiotherapy which are critical in patient survival. Our goal in this area is to develop new and more specific radiopharmaceuticals and radionuclide-based targeted therapeutic agents, that are required for the diagnosis of cancers and for monitoring the efficacy of anti-cancer therapy.
Dr. György Trencsényi
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- radiopharmaceuticals
- cancer
- radiochemistry
- in vitro and in vivo characterization
- targeted therapy
- in vivo imaging
